Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep 13;8(10):569-678.
doi: 10.1038/nrurol.2011.117.

Therapeutic Potential of Targeting Sphingosine Kinase 1 in Prostate Cancer


Therapeutic Potential of Targeting Sphingosine Kinase 1 in Prostate Cancer

Dmitri Pchejetski et al. Nat Rev Urol. .


Sphingosine kinase 1 (SK1) is a lipid enzyme with oncogenic properties that converts the proapoptotic lipid sphingosine into the antiapoptotic lipid sphingosine-1-phosphate, which activates the signal transduction pathways that lead to cell proliferation, migration, activation of the inflammatory response and impairment of apoptosis. Compelling evidence suggests that SK1 activation contributes to cancer progression leading to increased oncogenic transformation, tumor growth, resistance to therapies, tumor neovascularization and metastatic spread. High levels of SK1 expression or activity have been associated with poor prognosis in several cancers, including those of the prostate. Recent studies using prostate cancer cell and mouse models demonstrate a significant potential for SK1-targeting therapies to synergize with the effects of docetaxel chemotherapy and radiotherapy. However, until recently the absence of clinically applicable SK1 inhibitors has limited the translation of these findings into patients. With the recent discovery that clinically approved drug fingolimod has SK1-inhibiting properties, SK1 has gained significant attention from both clinicians and the pharmaceutical industry and it is hoped that trials of newly developed SK1 inhibitors might follow soon.

Similar articles

See all similar articles

Cited by 21 articles

See all "Cited by" articles


    1. Biol Pharm Bull. 2008 Jun;31(6):1177-81 - PubMed
    1. Mol Endocrinol. 2003 Oct;17(10):2002-12 - PubMed
    1. Cancer Lett. 2003 Sep 10;199(1):53-60 - PubMed
    1. J Biol Chem. 2004 Dec 24;279(52):53994-4001 - PubMed
    1. Mol Biol Cell. 2010 Mar 15;21(6):1111-24 - PubMed

MeSH terms